Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin

Clinical Pharmacokinetics

Volumn 42, Issue 10, 2003, Pages 921-929

  Yu, Zhiling ^a   Sefton, John ^a   Lew Kaya, Deborah A ^a   Walker, Patricia S ^a   Yu, Dale ^a   Tang Liu, Diane D S ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; TAZAROTENE; TAZAROTENIC ACID; UNCLASSIFIED DRUG;

ACNE VULGARIS; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN DEFECT; SKIN IRRITATION;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; FEMALE; HUMANS; MALE; NICOTINIC ACIDS; OINTMENTS; PHOTOSENSITIVITY DISORDERS; TIME FACTORS;

EID: 0041660705     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342100-00004     Document Type: Article

References (9)

1. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997; 37: 85-92
2. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis 1999; 63: 349-54
3. Bernard BA. Adapalene, a new chemical entity with retinoid activity. Skin Pharmacol 1993; 6: 61-9
4. Eckhoff C, Nan H. Identification and quantitation of all-transand 13-cis-retinoic acid and 13-cis-4-oxoretinoic acid in human plasma. J Lipid Res 1990; 31: 1445-54
5. Buchan P, Eckhoff C, Caron D, et al. Repeated topical administration of all-trans-retinoic acid and plasma levels of retinoic acids in humans. J Am Acad Dermatol 1994; 30: 428-34
6. Tang-Liu DD, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 1999; 37: 273-87
7. Yu Z, Yu D, Sefton J, Tang-Liu DDS. Study report PK-00-084: a therapeutic drug monitoring report for Allergan study 190168-029C-01 titled 'A multi-center, double-blind, randomized, vehicle-controlled, parallel-group study of the safety and efficacy of tazarotene cream 0.1% applied once daily for 12 weeks in patients with acne vulgaris'. Irvine (CA): Allergan, 2000 (data on file)
8. Yu Z, Yu D, Lew-Kaya DA, Tang-Liu DDS. Study report PK-01-082: a therapeutic drug monitoring report of tazarotenic acid based on weeks 36 and 52 data collected from Allergan study 190168-033C-00 titled 'A multi-center, double-blind, randomized, vehicle-controlled, parallel-group comparison of the safety and efficacy of tazarotene cream 0.1% applied once daily for 24 weeks followed by treatment with tazarotene cream 0.1% (open-label) for 28 weeks in patients with photodamaged facial skin'. Irvine (CA): Allergan, 2001 (data on file)
9. Sunscreen drug products for over-the-counter human use; final monograph. USA Food and Drug Administration Federal Register 1999; 64: (98)